BC Extra | Sep 26, 2019
Clinical News

Enanta dips on concerns about pruritus, differentiation of NASH compound

Dose selection for an upcoming trial could prove crucial among Enanta’s next steps for its FXR agonist following a Phase II readout in NASH that raised questions about the compound’s tolerability and differentiation from others...
BC Innovations | Feb 28, 2019
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest agonizing FXR could help treat colorectal cancer. In colorectal cancer patient samples, low tumor expression of an FXR-induced gene signature was associated with poor...
BC Week In Review | Oct 27, 2017
Clinical News

Enanta reports Phase I data for NASH/PBC candidate

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) reported data from a Phase Ia/Ib trial in 98 healthy volunteers and 48 patients with presumed non-alcoholic fatty liver disease (NAFLD) showing that oral EDP-305 was generally well tolerated with no...
BC Week In Review | Oct 10, 2016
Clinical News

EDP-305: Phase I started

Enanta began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single doses of oral EDP-305 and once-daily doses for 14 days in 90 healthy volunteers and patients with presumptive non-alcoholic fatty liver disease...
Items per page:
1 - 4 of 4